The reason for choosing raloxifene in peri-implant healing of osteoporosis conditions instead of other drugs, such as bisphosphonates, is because this drug is the only one to present a nearly physiologic effect, acting on estrogen receptors. Here, ESR1 is linked to osteoporosis.